Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
13 déc. 2021 10h30 HE
|
Allogene Therapeutics, Inc.
ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve PatientsAlloCAR T Therapy was Associated with Consistent and...
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
01 déc. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:...
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
12 nov. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
04 nov. 2021 16h02 HE
|
Allogene Therapeutics, Inc.
New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral...
Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology
04 nov. 2021 09h05 HE
|
Allogene Therapeutics, Inc.
ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell LymphomaALPHA Study Abstract...
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
28 oct. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
07 oct. 2021 16h15 HE
|
Allogene Therapeutics, Inc.
Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to TherapyInvestigation...
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
20 sept. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
01 sept. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
12 août 2021 08h30 HE
|
Allogene Therapeutics, Inc.
ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma PatientsPhase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time...